Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-vaccination anti-SARS-CoV-2 antibody response dynamics in National Institute of Public Health employees and volunteers
2021-000633-14Phase 4Completed
- Sponsor
- Staatliches Gesundheitsamt
- Start
- Feb 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by Staatliches Gesundheitsamt. Primary endpoints: Seroconversion at least 28 days after second dose, Seroconversion around 21 days after first dose and 1 more. Started Feb 2021; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-000633-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000633-14.